We are advancing innovative science and transformative medicines for people living with inflammatory and autoimmune diseases, including a portfolio of first in class programs and innovative development approaches across inflammatory bowel disease (IBD), respiratory, and rheumatological diseases.
Promedior – acquisition to further develop and commercialise PRM-151, a first-in-class recombinant human pentraxin-2 molecule targeted at preventing and potentially reversing fibrosis
Rheos – collaboration, option and license agreement with Roche to discover, develop and commercialise novel therapeutics in the field of immunometabolism
Parvus – collaboration to develop, manufacture and commercialise novel Navacim therapeutics to drive tolerance in inflammatory bowel disease, autoimmune liver disease and celiac disease
Patrick Schleck, Head of Immunology & Infectious Diseases, Pharma Partnering
Enza di Modugno, Site Head Immunology & Infectious Diseases (Basel), Pharma Partnering